Clinical Trials for Ark Therapeutics

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Ark Therapeutics

Clinical Trials (8)

NCT06826612
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
PHASE1/PHASE2Recruiting
53 participants
Started: Feb 21, 2025 · Completed: Jan 12, 2035
1 condition1 sponsor3 locations
NCT06828861
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
PHASE3Recruiting
90 participants
Started: Dec 20, 2024 · Completed: Apr 30, 2026
2 conditions1 sponsor44 locations
NCT07197034
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
PHASE3Recruiting
90 participants
Started: Jul 23, 2024 · Completed: Apr 30, 2027
3 conditions1 sponsor36 locations
NCT04093349
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
PHASE1/PHASE2Active, not recruiting
4 participants
Started: Oct 1, 2020 · Completed: Apr 30, 2032
7 conditions1 sponsor29 locations
NCT03432520
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
N/AActive, not recruiting
29 participants
Started: Aug 14, 2018 · Completed: Dec 31, 2032
1 condition1 sponsor12 locations
NCT03602820
Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
N/AActive, not recruiting
41 participants
Started: Jun 30, 2015 · Completed: Jan 31, 2030
1 condition1 sponsor0 locations
NCT00999609
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
PHASE3Active, not recruiting
31 participants
Started: Oct 31, 2012 · Completed: Jan 31, 2030
2 conditions3 sponsors2 locations
NCT01208389
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
PHASE1/PHASE2Active, not recruiting
12 participants
Started: Nov 30, 2010 · Completed: Oct 31, 2027
1 condition1 sponsor1 location